Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratympanic triamcinolone versus dexamethasone for sudden sensorineural hearing loss
IRCT20171004036554N4Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute sensorineural hearing loss comparing Intratympanic triamcinolone with Intratympanic dexamethasone (2 arms). Primary endpoint: Hearing improvement based on audiometry. Started Jan 2022; status: completed.
02
Drugs
triamcinolonedexamethasone
03
Conditions
acute sensorineural hearing loss
Beyond the preview
Go deeper on IRCT20171004036554N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171004036554N4.